• Explore /
  • Poster
  • / Outcomes of enfortumab vedotin (EV) therapy in relation to prior immune checkpoint inhibitor (ICI) in patients (pts) with advanced urothelial cancer (aUC).

Outcomes of enfortumab vedotin (EV) therapy in relation to prior immune checkpoint inhibitor (ICI) in patients (pts) with advanced urothelial cancer (aUC).

Abstract Poster

Authors

null

Evangelia Vlachou

Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD

Evangelia Vlachou , Roy Elias , Noah M. Hahn , David James McConkey , Burles Avner Johnson III, Jean H. Hoffman-Censits

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Urothelial Carcinoma

Track

Urothelial Carcinoma

Sub Track

Quality of Care/Quality Improvement and Real-World Evidence

Citation

J Clin Oncol 42, 2024 (suppl 4; abstr 570)

DOI

10.1200/JCO.2024.42.4_suppl.570

Abstract #

570

Poster Bd #

E19

Abstract Disclosures

Similar Posters

Poster

2023 ASCO Genitourinary Cancers Symposium

Uptake of maintenance immunotherapy and changes in upstream treatment selection in patients with advanced urothelial cancer (aUC).

Uptake of maintenance immunotherapy and changes in upstream treatment selection in patients with advanced urothelial cancer (aUC).

First Author: Ronac Mamtani

First Author: Evangelia Vlachou

First Author: Haojie Li

First Author: Lorenzo Pilla